Nanobody‐based CAR‐T cells can function as an antitumor agent in tumor microenvironment and tumor xenograft models, such as CD19 CAR‐T, CD70 CAR‐T, CD72 CAR‐T, CD105 CAR‐T, which are engineered by CRISPR/Cas9 and in silico techniques [300, 301, 302, 303]. Here, CD19 is linked to neoplasm.